Last Updated: 08/06/2026

Link Biologics

Manchester

Founded 2021

TSG-6 protein therapeutics for inflammatory and degenerative disease

Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties.

Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in dry eye disease and osteoarthritis.

A licensing partnership with Théa Open Innovation supports development of the dry eye programme toward clinical trials.

Biotech Immunology Drug Discovery

Autoimmune Disease Eye Health Musculoskeletal Peptide Therapeutics

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

BioIndustry Association

Similar Companies